Randomized controlled trials

A randomized controlled trial (RCT) is a type of scientific experiment, widely regarded as the gold standard for evaluating the effectiveness of a medical intervention, such as a new drug, surgical procedure, or public health program. Its core principles are the use of a control group for comparison and the random assignment of participants to either the intervention group or the control group. The intervention group receives the new treatment being tested, while the control group receives a standard treatment, a placebo (an inactive substance), or no intervention at all.

The process of randomization is the cornerstone of the RCT. By allocating participants to groups by chance, similar to flipping a coin, researchers minimize selection bias and ensure that the groups are, on average, comparable in all known and unknown characteristics at the outset. This balancing of variables means that any significant differences in outcomes observed between the groups at the end of the study can be confidently attributed to the intervention itself, rather than to pre-existing disparities. To further reduce bias related to expectations, many RCTs are "blinded." In a double-blind trial, neither the participants nor the researchers administering the treatment know who is in which group, preventing this knowledge from influencing behavior or assessments.

In the framework of evidence-based medicine, RCTs occupy a high position in the hierarchy of evidence, surpassed only by systematic reviews and meta-analyses that synthesize the findings of multiple high-quality RCTs. They provide stronger causal evidence than observational studies (e.g., cohort studies, case-control studies), where researchers observe outcomes without controlling the assignment of treatment. While valuable, observational designs are more vulnerable to confounding variables—external factors that can distort the apparent relationship between an intervention and an outcome.

For patients, clinicians, and policymakers, RCTs are essential for making informed healthcare decisions. They provide the most reliable evidence to determine whether a new therapy is not only effective but also safe compared to existing options. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), typically require robust data from well-conducted RCTs before approving new medicines for public use. Despite their strengths, RCTs have limitations. They can be expensive, time-consuming, and sometimes ethically or practically unfeasible. Furthermore, the highly controlled conditions and specific patient populations of some trials may not always reflect the complexities of real-world clinical practice, raising questions about the generalizability of their findings.